Bladder-sparing treatment for muscle-invasive bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, to treat bladder cancer that has grown into the muscle of the bladder. The goal is to shrink or eliminate the cancer so that surgery to remove the bladder may not be needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with muscle-invasive bladder cancer that has not spread beyond the bladder (stage T2-3N0M0).
- You have had a procedure called a transurethral resection of bladder tumor (TURBT) within the last 90 days to remove as much of the tumor as possible.
- You are healthy enough to undergo surgery to remove the bladder, if needed.
- Your kidney, liver, and blood cell counts are within acceptable ranges.
- You have not had chemotherapy for this bladder cancer before, and you have not had radiation therapy to the bladder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, to see if they can control muscle-invasive bladder cancer without needing to remove the bladder. It may be an option for people who want to try to preserve their bladder and avoid surgery or radiation.
This trial tests whether two drugs (enfortumab vedotin and pembrolizumab) work better than radiation with chemotherapy for muscle-invasive bladder cancer. The goal is to treat your cancer while keeping your bladder instead of removing it.
This trial adds an investigational drug, GB-4362, to a standard combination of two medicines (enfortumab vedotin and pembrolizumab) for advanced bladder cancer. The study wants to see if adding this drug is safe and helps treat the cancer better.
This study tests two drugs, enfortumab vedotin and pembrolizumab, to see if they can help people with muscle-invasive bladder cancer avoid removing their bladder. The drugs are given before the standard surgery to possibly shrink the tumor and improve outcomes.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) to see if it can help people with muscle-invasive bladder cancer avoid bladder removal surgery. The goal is to preserve the bladder while still treating the cancer effectively.
This trial tests a two-drug combination (pembrolizumab and enfortumab vedotin) followed by maintenance pembrolizumab for people with advanced bladder cancer that has not been treated before. The goal is to see if this approach helps control the cancer for longer.
Hear when a new Muscle Invasive Bladder Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.